Mayo Clinic researchers report that AI-enabled spatial analysis of standard pathology slides can predict pancreatic cancer recurrence risk more accurately than volume-based methods, according to a study in Clinical Cancer Research.
Yourgene Health has launched its IVDR-certified DPYD assay in Europe, enabling detection of 19 DPYD gene variants to help clinical labs identify cancer patients at risk of severe toxicity from fluoropyrimidine chemotherapy.
The FDA has cleared Roche's Elecsys pTau217 blood test to aid in identifying Alzheimer disease amyloid pathology, marking the first single-biomarker assay for both rule-in and rule-out use on existing lab instruments.
FDA clearance of the BD Onclarity Self-Collection Kit in April 2026 enables at-home HPV testing for cervical cancer screening, expanding access and addressing barriers for under-screened populations.
A study found that use of IBS-Smart and Trio-Smart tests was linked to fewer colonoscopies and lower diagnostic costs among adults with suspected irritable bowel syndrome.
Exome sequencing identified genetic causes in 12% of unexplained premature ovarian insufficiency cases, according to University of Tartu researchers, highlighting potential for broader genetic testing.
A Vanderbilt study finds that standard genetic tests for lamotrigine reaction risk omit HLA-A*32:01, a marker linked to severe DRESS, raising concerns about current pharmacogenomic panel effectiveness.
Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.
Seed Healthcare has led a strategic investment in Diadem to support US commercialization of AlzoSure Predict, a blood-based Alzheimer’s diagnostic recently validated in over 900 patients and designated a Breakthrough Device by the FDA.
A University of Exeter study finds that adding a genetic risk score to MODY testing can identify hidden type 1 diabetes in 16% of patients with negative genetic results, supporting updated NHS diagnostic protocols.
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A study validates Nu.Q NETs H3.1 nucleosomes as independent predictors of 28-day mortality and renal replacement therapy need in sepsis and septic shock, according to VolitionRx.